Equibles does not estimate personal net worth.
Get an email with a short summary when Enanta Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get ENTA alertsPaul Mellett is recorded as CFO at Enanta Pharmaceuticals Inc (ENTA). The newest filing on record that lists Paul Mellett as CFO at Enanta Pharmaceuticals Inc (ENTA) is dated January 20, 2023. The proxy statement of Enanta Pharmaceuticals Inc reports total compensation of $1,136,539 for Paul Mellett in fiscal 2024, including a base salary of $486,325. Disclosed compensation is on record for 8 fiscal years. Paul Mellett has spoken on 18 earnings calls across 1 company, most recently for Enanta Pharmaceuticals Inc on May 6, 2024. Enanta Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Enanta Pharmaceuticals Inc includes Harry R. Trout, III (CFO), Tara L. Kieffer, Ph.D. (COO), Nathaniel S. Gardiner (General Counsel) and 4 others.
“I would like to remind everyone that Enanta reports on a September 30 fiscal year schedule. Today, we are reporting results for our fiscal second quarter ended March 31, 2024.”
“I'd like to remind everyone that Enanta reports on the September 30 fiscal year schedule. Today, we are reporting results for our fiscal first quarter ended December 31, 2023.”
“I'd like to remind everyone that Enanta reports on a September 30 fiscal year schedule. Today, we are reporting results for our fourth quarter and full year ended September 30, 2023.”
“For the quarter, total revenue was $18.9 million and consisted of royalty revenue earned on AbbVie’s global MAVYRET net product sales. This compares to total revenue of $19.5 million for the same period in 2022.”
“Before I provide details on our second quarter financial results, I also want to take a moment to comment on our royalty sales transaction, which we announced in April.”
Start not stated–present
Last confirmed January 20, 2023
Proxy statement
Start not stated–2025-01-27
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Enanta Pharmaceuticals Inc (ENTA) | Chief Financial and Administrative Officer | $486,325 | $1,136,539 |
| 2023 | Enanta Pharmaceuticals Inc (ENTA) | Chief Financial and Administrative Officer | $453,975 | $2,375,714 |
| 2022 | Enanta Pharmaceuticals Inc (ENTA) | Chief Financial and Administrative Officer | $440,381 | $1,887,570 |
| 2021 | Enanta Pharmaceuticals Inc (ENTA) | Chief Financial and Administrative Officer | $440,381 | $1,887,570 |
| 2020 | Enanta Pharmaceuticals Inc (ENTA) | Senior Vice President, Finance & Administration and Chief Financial Officer | $425,894 | $1,781,843 |
| 2019 | Enanta Pharmaceuticals Inc (ENTA) | Senior Vice President, Finance & Administration, Chief Financial Officer | $411,775 | $1,531,563 |
| 2018 | Enanta Pharmaceuticals Inc (ENTA) | Senior Vice President, Finance & Administration and Chief Financial Officer | $370,728 | $1,607,853 |
| 2017 | Enanta Pharmaceuticals Inc (ENTA) | Senior Vice President, Finance & Administration and Chief Financial Officer | $370,728 | $1,607,853 |
